
A brisk walk a few times a week could help keep colon cancer away, study suggests
James Smith woke up from a colonoscopy to be told devastating news. At 59, he was diagnosed with colon cancer. Doctors found a mass so large it completely blocked their view of the rest of his colon. Smith said he was shocked.
"It was hard, it was a hard diagnosis," he said. "It was hard to believe it was actually happening."
Smith underwent surgery and four rounds of chemotherapy. When his doctors suggested he join a study to examine regular exercise and its possible role in preventing cancer recurrence, he said yes. He was concerned — through the course of his treatment he had lost about 26 kilograms, as well as muscle mass. But he joined, anyway.
"At the beginning it was difficult, I won't deny. It was like, 'How am I going to do all this?'"
Though he wasn't included in the final study, he ended up finding the program helped him gain a sense of control over the cancer and his treatments. Smith is now cancer-free and his prognosis is good, he says.
The study, which was published in the New England Journal of Medicine on Sunday, found that for patients with colon cancer, structured exercise did make a difference. Seven years after being diagnosed, 90 per cent of the patients who took part in the structured exercise program over a three-year period were still living. In the group that had only received an informational pamphlet, 83 per cent of participants were still alive.
The researchers don't know exactly why the program had such an impact. But the findings could have significant future implications for how patients with colon cancer, one of the most common cancers, receive treatment.
Helping with traditional treatments
The study enrolled 889 patients from 55 hospitals in Canada, Australia and the United Kingdom. The clinical trial focused on high-risk stages 2 and 3 colon cancer patients who had received surgery and chemotherapy. Half of the group was given the traditional take-home pamphlet recommending diet and exercise and the other half was prescribed a structured exercise program for three years. The study lasted for 15 years, with about half of the participants joining in the beginning and the rest later on.
Patients in the exercise group were assigned a physiotherapist or a personal trainer to check in with at least once a month. But they were free to decide what kind of exercise they wanted to do. They just had to do it for up to 45 minutes, depending on the type, three times a week. For Smith, that meant walking briskly on a treadmill. Other participants biked, swam or hit the gym. In each case, the exercise had to include a sustained, elevated heart rate. (They didn't specify a figure.)
"If someone saw you walking, they would think you are late for an appointment," said Kerry Courneya, a kinesiology professor at the University of Alberta and the lead author of the study.
Courneya launched the research because previous studies had hinted at the benefits of exercise, but nothing was definitive enough to convince doctors. The exercise program is not meant to replace traditional treatments, like surgery and chemotherapy, but is meant to enhance them.
"There was a lot of skepticism with the observational studies, and many health-care providers and oncologists felt like they didn't act on them because they were methodologically limited."
Researchers found differences in cancer recurrence, as well. Eighty per cent of the exercise group was cancer-free five years after their diagnosis, compared with about 74 per cent in the group that received the pamphlet. Colon cancer typically recurs in about 30 to 40 per cent of patients.
Benefits comparable to some chemo drugs
Dr. Chris Booth is a senior author of the study and an oncologist at Queen's University in Kingston. Booth suggests that when combined with traditional treatments, the benefits of the prescribed exercise program are comparable to some chemo drugs.
"There are treatments we use every day that have much smaller benefits and some of the treatments we think are important have benefits that are comparable to this [exercise]."
Dr. Sami Chadi is a colorectal surgeon and clinician investigator at the Princess Margaret Cancer Centre, part of Toronto's University Health Network. He was not involved in the research, and already encourages his patients to exercise. But he says he plans to use this research to help convince his patients to follow a structured exercise routine.
"I don't think there is any question about it. I think a structured exercise program after surgery and after treatment is absolutely necessary, so we should be strongly recommending it as strongly as we recommend chemotherapy to our Stage 3 patients."
The researchers don't know why exactly the exercise program impacted the recurrence and improved survival. They do know it wasn't about weight loss or improved cardiovascular function, because there was no significant change in either factor during the study. Dr. Booth describes it as a mystery that he aims to solve.
"We banked blood on all the patients," he said. "In the next couple of years, we will be doing detailed biomarker analysis to try and understand what it is about exercise that is reducing the risk of cancer recurrence."
WATCH | Dr. Booth on the study's findings:
Prescribed exercise could be as effective as chemo for colon cancer, researcher says
2 minutes ago
Duration 1:25
Dr. Christopher Booth, oncologist from Queen's University, discusses the results of his study that looked at the impact of an exercise program on people with colon cancer.
In the meantime, he says this study should give enough evidence to convince patients, doctors and governments that structured exercise programs should be an important part in their arsenal to reduce the risk of a recurrence of colon cancer.
As for Smith, it's been nearly five years since his diagnosis. He is doing well and still exercising and playing hockey in Edmonton. Recurrence is still something he worries about, but he's thrilled to hear the results of the research, calling them fantastic.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
an hour ago
- Globe and Mail
Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase Ib/II study of the investigational Bcl-2 inhibitor, lisaftoclax (APG-2575), in combination with hypomethylating agent azacitidine in patients with treatment-naïve (TN) or prior venetoclax-exposed myeloid malignancies, in an oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. As Ascentage Pharma returns to the ASCO Annual Meeting for the eighth consecutive year, two studies of lisaftoclax and MDM2-p53 inhibitor alrizomadlin (APG-115), key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations, including an oral presentation. This oral presentation reported results from a multi-country, multi-center Phase Ib/II study of lisaftoclax, which as of data cutoff in April 2025, enrolled a total of 103 patients, including patients with TN or relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Findings of this study once again underscored the promising antitumor activity and manageable tolerability of lisaftoclax in myeloid malignancies. Furthermore, for the first time, this study reported responses in venetoclax-refractory patients who received lisaftoclax, thus suggesting that lisaftoclax has favorable antitumor activity and is differentiated from other drugs in the same class. Lisaftoclax is a novel Bcl-2 inhibitor developed by Ascentage Pharma. In November 2024, the New Drug Application (NDA) for lisaftoclax for the treatment of R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was accepted and granted a Priority Review designation by the Center for Drug Evaluation (CDE) of China's National Medical Product Administration (NMPA). With this submission, lisaftoclax has become the first China-developed Bcl-2 inhibitor to reach NDA submission in China, and the second Bcl-2 inhibitor with submitted NDAs anywhere in the world. At present, lisaftoclax is being evaluated in four global registrational Phase III studies in major indications such as CLL/SLL, AML, and MDS, including a US Food and Drug Administration (FDA)-cleared multi-country, registrational Phase III trial. Patricia Kropf, MD, Principal Investigator of the study from Novant Health Cancer Institute, commented, 'In this global, multicenter study, lisaftoclax in combination with azacitidine showed promising efficacy and a tolerable safety profile for patients with treatment-naïve or R/R AML and MDS. This data supports the upcoming Phase III study using the combination therapy for this patient population. Interestingly, lisaftoclax showed the potential to overcome resistance to venetoclax in patients who failed prior treatment with venetoclax, suggesting that it might bring improved treatment outcome. We look forward to releasing more data from this study which will further validate lisaftoclax's broad therapeutic potential.' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'In previous studies, lisaftoclax combined with azacitidine has already demonstrated significant activity in patients with various myeloid malignancies. In this oral presentation, we report the latest data from a multi-country, multicenter Phase Ib/II study that showed promising antitumor activity and good tolerability of the combination regimen in myeloid malignancies such as AML and MDS. In particular, lisaftoclax has shown therapeutic potential in venetoclax-refractory patients, making this study the first that reported a Bcl-2 inhibitor overcoming drug resistance to another Bcl-2 inhibitor, thus suggesting that lisaftoclax may bring about a breakthrough to the treatment of myeloid malignancies. For now, lisaftoclax is being evaluated in multi-countries, registrational Phase III studies in AML and MDS. We remain committed to our mission of addressing unmet clinical needs in China and around the world and plan to further accelerate our clinical programs to bring more novel therapeutics to patients as soon as possible.' Highlights of this abstract selected for presentation at ASCO 2025 are as follows: Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined with Azacitidine (AZA) in Patients with Treatment-Naïve or Prior Venetoclax-Exposed Myeloid Malignancies Abstract #: 6505 Format: Oral Presentation Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Principal Authors: Michael Francis Leahy, MBChB, Royal Perth Hospital, Australia; Shaun Fleming, MBBS(Hons), PhD, The Alfred Hospital & Australian Centre for Blood Diseases, Australia; Patricia Kropf, MD, Novant Health Cancer Institute, United States, et al. Highlights: Background: AML and MDS are hematologic malignancies with poor prognoses. Hypomethylating agents (HMAs) AZA and decitabine are approved for MDS and AML and have been shown to prolong survival in patients. However, additional treatment options that improve clinical outcomes, such as complete response (CR) and overall survival (OS), are needed. Lisaftoclax is an investigational, orally active, small-molecule Bcl-2 inhibitor that has shown enhanced treatment responses in AML and MDS when combined with AZA in preclinical 1 and clinical 2 studies. Efficacy results: As of the data cutoff in April 2025, 22 of 28 venetoclax-refractory patients with R/R AML/ Mixed Phenotype Acute Leukemia (MPAL) were efficacy-evaluable, among whom, the overall response rate (ORR) was 31.8%, including 22.8%, 4.6%, and 4.6% achieving CR/CR with incomplete hematologicrecovery (CRi), partial response (PR), and the morphologic leukemia-free state (MLFS), respectively. All responsive patients had received multiple lines of therapy that included venetoclax, and most of them (71%, 5/7) harbored the TP53 mutation and had a complex chromosomal karyotype at baseline. In 6 efficacy-evaluable patients with newly diagnosed (ND) AML/MPAL, the ORR was 83.3%, with CR/CRi and PR achieved by 33.3% and 50% of patients, respectively. In 44 efficacy-evaluable patients with R/R AML/MPAL, the ORR was 43.2%, with CR/CRi, PR, and MLFS achieved by 31.8%, 4.5%, and 6.8% of patients, respectively. In 15 efficacy-evaluable patients with ND MDS/chronic myelomonocytic leukemia (CMML), the ORR was 80%, with CR and marrow CR (mCR) achieved by 40% and 40% of patients, respectively. In 22 efficacy-evaluable patients with R/R MDS/CMML, the ORR was 50%, with CR, mCR, and PR achieved by 27.3%, 18.2%, and 4.5% of patients, respectively. Safety results: Lisaftoclax in combination with AZA was well tolerated, with a manageable profile. Common adverse events were mostly hematologic. Nonhematologic toxicity was uncommon. The majority of adverse events were manageable, reversible and tolerable. Conclusions: Lisaftoclax combined with AZA showed promising antitumor activity and favorable tolerability in patients with TN or R/R myeloid malignancies. Furthermore, lisaftoclax demonstrated the ability to overcome drug resistance to venetoclax, making this the first clinical study to report a Bcl-2 inhibitor overcoming venetoclax resistance. * Lisaftoclax (APG-2575) is an investigational compound and has not been approved by the US FDA. Reference: 1 Zhai Y, Tang Q, Fang DD, et al. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies. Clin Cancer Res. 2023;29:183-196. 2 Wang H, Wei X, Jiang Q, et al. Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms. Blood 2023;142(Suppl 1):2925. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first third generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph + ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematological malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with sub-optimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma +86 512 85557777 Stephanie Carrington ICR Healthcare +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare +1 (646) 866-4012


CBC
2 hours ago
- CBC
Talk with the Doc returns with advice about sore shoulders, recurring colds, and more
Dr. Trevor Jain is back for another episode of Talk with the Doc, talking to Louise Martin of CBC News: Compass about everything from shoulder surgery and the wait times for an MRI to what to do about a recurring cold. Jain is an emergency room physician at the Queen Elizabeth Hospital in Charlottetown.


National Post
2 hours ago
- National Post
Beauty Buzz: The 3 best beauty products we tried this week from Chanel, The Maker and Revlon
We try dozens of beauty products each month. These were our testers' three favourite launches this week: Article content Article content Article content The Maker Revel Eau de Parfum Article content They say: A new fragrance release from The Maker, this fruity-floral scent feature notes of lychee, pineapple, rosewater and Frangipani flower. It's a 'main character' fragrance, according to the brand. Article content We say: If you haven't yet checked out the brand The Maker, it's high time that you did. Our testers can attest to their ongoing appreciation for the fragrance collection. (The Lover scent is a particular favourite!). The latest scent is fruity and fresh, but the base of floral and velvet musk keep it from skewing too sweet. It's a delightful scent for summer. Article content Article content They say: The fan-favourite Les Beiges makeup collection expands with the limited-edition release of the Golden Hour Collection. Among the summer launch is the two-tone Illuminating Power Duo. Available in two colour tones, the ultrafine powder features an illuminating powder and a bolder blush tone. Article content Article content